Aiforia’s €12.6 Million Series B Financing Round First Tranche

Merilampi represented Epredia in the transaction.

Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology, announced the closing of the first €12.6M tranche of their Series B round. The funding round has the potential to reach €25.2M if investors exercise the optional second tranche.

The funding round is led by Epredia’s UK entity, a subsidiary of PHC Holdings Corporation. Investors also include Aktia Nordic Micro Cap and existing shareholders. KPMG acted as a financial advisor to Aiforia in the successful Series B round.

Aiforia’s cloud-based software currently has over 3,000 users in more than 50 countries. The funding round helps strengthen the company’s global presence for pharmaceutical companies looking to accelerate their drug development pipeline with deep learning AI powered solutions — as well as the development and release of Aiforia’s novel platforms for the diagnosis of the world’s most prevalent cancers.

Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings in 2019. Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world.

The Merilampi team included Antti Kahri (Picture), Niko Kolsi and Hilma Parvela.

Involved fees earner: Antti Kahri – Merilampi Attorneys Ltd.; Niko Kolsi – Merilampi Attorneys Ltd.; Hilma Parvela – Merilampi Attorneys Ltd.;

Law Firms: Merilampi Attorneys Ltd.;

Clients: Epredia;

Federica Tiefenthaler

Author: Federica Tiefenthaler